Mecta spectrum 5000Q device
DeviceLAP-ST and Right Unilateral (RUL) electrode placement.
NCT Number: NCT02928159
This study assesses the feasibility of a full course of Low Pulse Amplitude-Seizure Therapy (LAP-ST) (primary outcome).
Looking for future studies?
Notify Me20 year–80 year
All sexes
Interventional
Phase 1
This is hypothesized to increase stimulation focality, thus minimizing cognitive side effects compared to conventional ECT. The study will enroll 22 patients recruited from the Behman Hospital, Cairo, Egypt. Patients referred to ECT service in the Behman Hospital who are clinically indicated to do ECT for major depressive episode of a mood disorder or psychotic episode of a primary psychotic disorder will be approached. Eligible participants who signed informed consent will be included to receive a course of Right Unilateral Ultrabrief LAP-ST.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
LAP-ST and Right Unilateral (RUL) electrode placement.
Time frame: From first to last session of LAP-ST course (average approximately 2 weeks)
Measured by: the elicitation of therapeutic seizure in the brain and assessed by using EEG
Time frame: From Baseline to end of acute course (average 2 weeks)
Measured by: Mini Mental State Examination
Time frame: From Baseline to end of acute course (average 2 weeks)
Measured by: Time to Orientation Test
Time frame: From Baseline to end of acute course (average 2 weeks)
Montgomery-Åsberg Depression Rating Scale (MADRS) for depressive episodes of mood disorders
Time frame: From Baseline to end of acute course (average 2 weeks)
Brief Psychiatric Rating Scale (BPRS) for psychotic disorders
Behman Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05321602
Antipsychotic Agents, Central Nervous System Depression
Little Rock, Arkansas, United States
View Trial DetailsNCT00363181
Body Weight, Body Weight Changes
Palo Alto, California, United States
View Trial DetailsNCT06038786
Anxiety Disorders, Mental Disorders
Charlestown, Massachusetts, United States
View Trial DetailsNCT04922593
Antipsychotic Agents, Central Nervous System Depressants
Garden Grove, California, United States
View Trial Details